Atriance launched for lymph cancer

GSK has launched Atriance (nelarabine) for the treatment of patients with T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma whose disease has not responded, or has relapsed, following treatment with at least two chemotherapy regimens.

Further information: GSK 0800 221441

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...